Taiwan ADC Companies and Pipelines
As of October 22, 2026, this table includes ADC programs or regionally licensed products at 8 Taiwan companies, with roles and source dates retained. [1] [2] [3] [4] [5] [6] [7]
The selected OBI Pharma and GlycoNex programs have entered clinical trials, while the selected PharmaEssentia and TaiMed ADCs remain preclinical; Formosa Pharmaceuticals and EirGenix co-develop the same TSY-110 / EG12043. [1] [2] [3] [4] [5] [6] [7]
| Company | Ticker | Product / pipeline | Indication | Latest verified stage | Stage source and date | Most recent catalyst |
|---|---|---|---|---|---|---|
| OBI Pharma Company source | 4174 | OBI-992 | Advanced solid tumors | Phase 1/2; active, not recruiting | 2025-08-08 Stage source ACTIVE_NOT_RECRUITING | — |
| GlycoNex Company source | 4168 | GNX1021 (ADC) | Advanced solid tumors (Phase 1 enrollment) | Phase 1; first patient dosed in Japan | 2026-08-03 Stage source Phase 1 clinical trial of GNX1021 | First patient dosing in Japan announced on August 3, 2026. 2026-08-03 Source first patient |
| Formosa Pharmaceuticals Company source | 6838 | TSY-110 / EG12043 (co-developed with EirGenix) | HER2-positive metastatic and early-stage breast cancer | European clinical trial application submitted | 2026-08-28 Stage source Clinical Trial Application (CTA) | — |
| EirGenix Company source | 6589 | EG12043 / TSY-110 (co-developed with Formosa Pharmaceuticals) | HER2-positive metastatic and early-stage breast cancer | Co-developed program: European CTA submitted | 2026-08-28 Stage source Clinical Trial Application (CTA) | — |
| PharmaEssentia Company source | 6446 | ADC (novel target; individual code undisclosed) | Solid tumors | Preclinical; IND-enabling | 2026-08-25 Stage source IND ENABLING | The company plans an IND for this ADC in 2027; this is planned, not a submitted filing. 2026-08-25 Source Planned IND in 2027 |
| TaiMed Biologics Company source | 4147 | TMB-HIV ADC | HIV treatment / cure research | Preclinical | 2026-07 Stage source 臨床前 Preclinical | — |
| Synmosa Biopharma Company source | 4114 | Tivdak (Taiwan distribution and commercialization rights) | Recurrent or metastatic cervical cancer | Taiwan filing submitted; company role is commercialization | 2026-03-12 Stage source 台灣已送件 | — |
| Orient EuroPharma Company source | 4120 | TE-1146 (Taiwan, ASEAN, Australia and New Zealand distribution rights) | Multiple myeloma | Preclinical development; regional licensee | 2026-10-22 Stage source 臨床前開發階段 | — |
Scope and public-document limits
This is a verified selection, not an industry census. Unverified trial starts, results and approval dates are not filled in.